Stock comparison
Boston Scientific
ResMed
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
BSX
Boston Scientific
Market cap
$85.88B
Sector
Healthcare
RMD
ResMed
Market cap
$30.18B
Sector
Healthcare
Overall winner
ResMed RMD
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | BSX | RMD | Winner |
|---|---|---|---|
| Warren Buffett | 63C | 72B | RMD |
| Benjamin Graham | 69B | 75B | RMD |
| Philip Fisher |
Side-by-side metrics
| Metric | BSX | RMD |
|---|---|---|
| Market cap | $85.88B | $30.18B |
| P/E (TTM) | 22.0x | 19.6x |
| EV/EBIT | 22.1x | 17.1x |
| ROIC (TTM) | 9.9% | 19.63% |
| Gross margin | 70.41% | 61.69% |
| Net margin | 17.24% | 27.44% |
| Revenue CAGR 5y | 13.99% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
BSX leads on
- Market cap$85.88Bvs $30.18B+65%
- Gross margin70.41%vs 61.69%+12%
- Revenue CAGR 5y13.99%vs 12.64%+10%
RMD leads on
More like RMD
Related on invest-like
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.